Hypocalcemia: ionized calcium and kidney disease

Educational use only. Not clinically reviewed

72-year-old woman for Qualified monitored rescue, measurement review, individualized continuing calcium and mineral care, reassessment, and follow-up handoff. About 60 simulated minutes.

What you will practise

Arrange qualified monitored rescue for symptomatic hypocalcemia.
Interpret measured ionized calcium alongside kidney disease and albumin.
Separate continuing calcium support from mineral care and follow-up.
Distinguish current ionized calcium, bedside symptoms, and historical findings.
Transfer unresolved risk with explicit continuing-care ownership.

Review and sources

Not clinically reviewed. No clinician has signed this scenario.

Gauci C, Moranne O, Fouqueray B, et al. Pitfalls of measuring total blood calcium in patients with CKD. Journal of the American Society of Nephrology. 2008;19:1592–1598. doi:10.1681/ASN.2007040449. Observational evidence about total, albumin-adjusted, and ionized calcium in kidney disease; no correction formula or authored trajectory is validated here.
Society for Endocrinology. Emergency management of acute hypocalcaemia in adult patients. Endocrine Connections. 2016;5:G7–G8. doi:10.1530/EC-16-0056. Qualified monitored emergency treatment, reassessment, and cause-specific continuing care; no calcium dose or rate is selected here.
Society for Endocrinology. Addendum: Emergency management of acute hypocalcaemia in adult patients. Endocrine Connections. 2019. doi:10.1530/EC-16-0056a. Updated preparation guidance does not make this dose-free simulation a prescribing tool.
U.S. Food and Drug Administration. Boxed Warning for severe hypocalcemia in patients with advanced chronic kidney disease taking Prolia (denosumab). January 19, 2024. Advanced kidney disease, mineral-bone disorder review, specialist involvement, and post-dose monitoring; an association does not prove the sole cause in this fictional patient.
DailyMed. Prolia (denosumab) injection prescribing information. Revised June 2026; checked August 27, 2026. Advanced kidney disease, calcium and activated-vitamin-D support, and monitoring require qualified individualized care. No dose, treatment duration, or future denosumab decision is simulated.

Every scenario in this module

Open Sim Lab is an educational simulator, not for clinical use. It is not a clinical decision-support tool, not a dosing calculator, and is not validated for any decision affecting a real patient.